MOUNT OLIVE, N.J., May 18, 2016 /PRNewswire/ -- Flowonix Medical, Inc., announced today that Larry Heaton has been appointed President and Chief Executive Officer of the Company, effective May 9, 2016. He will also serve on the Company's Board of Directors. Mr. Heaton brings over 34 years of experience in the medical device industry to Flowonix, with an extensive focus on commercialization in both large cap and early stage medical device companies in his career. Steve Adler, formerly the President and CEO of Flowonix, will remain on the Flowonix Board of Directors.
"It is with great pleasure that the Board and Flowonix welcome as experienced and commercialization-oriented leader as Larry Heaton as our new Chief Executive Officer," said David Jenkins, Founder and Chairman of the Board of Directors of Flowonix. "Larry has a track record of rapidly understanding and realizing the potential of emerging medical technologies. With growing momentum behind the launch of the Prometra® implantable drug delivery pump in the U.S. and Europe, we look forward to his contributions as Flowonix focuses on commercialization during its next stage of growth and development."
"The Prometra® pump represents a significant advancement in implantable drug delivery devices, bringing a level of safety and precision delivery of critical drugs needed for pain management not available in the market today," said Mr. Heaton. "With its unique capability to deliver precise doses as required, it also enables programmable delivery of additional drugs for new clinical indications where precision in dosage delivery is of the essence. The recently announced collaboration with Cerebral Therapeutics is the first example of this new area of opportunity for Flowonix, it's customers and the patients they serve. My goal is to see the Prometra® implantable drug delivery system emerge as the leading implantable device used for pain management and play the leading role in developing synergies between effective drugs and precise localized delivery. I look forward to working with the talented and dedicated team at Flowonix to make this a reality."
Most recently, Mr. Heaton was President, Chief Executive Officer and Director of Cardiox Corporation, a privately held company that developed and marketed drug-device combination products for the structural heart and liver diagnostics markets, joining the Company as its first employee.
Previously, he served as President, Chief Executive Officer and Chairman of the board of ViOptix Inc., a privately held company in the tissue oximetry field. Prior to that Mr. Heaton served as President, Chief Executive Officer and Director of Curon Medical, Inc., a public company marketing products for the treatment of gastrointestinal disorders. Prior to that, he was President, Chief Executive Officer and Director of Response Genetics, Inc., an applied genomics start-up firm, now public, providing gene expression services in the oncology market.
Mr. Heaton's earlier career spanned 18 years at United States Surgical Corporation, a leading manufacturer of innovative wound closure products and advanced surgical devices with annual sales exceeding one billion dollars. Serving in roles of increasing responsibility in Sales, Marketing and General Management, his career culminated in him serving as President and Chief Operating Officer of United States Surgical and its various subsidiary companies from 1998 through 2000.
Mr. Heaton has had seven U.S. patents issued to date with 15 additional patents pending, related to enhancements of products designed to facilitate their effective commercialization. He has served as a member of the board of several international medical societies and foundations, including the MITAC Board for the commercialization of NASA technology via partnerships with the medical industry.
Flowonix Medical Inc. (www.flowonix.com), headquartered in Mt. Olive, NJ, is dedicated to working with healthcare professionals to help ease suffering associated with chronic pain and allow patients to reclaim their lives through innovation and therapy advancements. The strategic business goal of Flowonix Medical Inc. is to become the leading implantable drug delivery company in the world. Founded in 2005, Flowonix Medical Inc. received approval to conduct its first clinical trial in 2007 on the Prometra® programmable implantable pump. The company received approval by the FDA to market the Prometra® in 2012. Flowonix Medical Inc. has been granted multiple patents, and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.
For more information, please visit http://www.flowonix.com.
SOURCE Flowonix Medical, Inc.